D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

(2022) Joshua K. Sabari et al.   CLINICAL CANCER RESEARCH

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

(2022) Andreas Weiss et al.   Cancer Discovery

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

(2020) Jenny Y. Xue et al.   NATURE

The Frequency of Ras Mutations in Cancer

(2020) Ian A. Prior et al.   CANCER RESEARCH

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

(2020) Yuta Adachi et al.   CLINICAL CANCER RESEARCH

Impact of P-Glycoprotein–Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates

(2020) Yoko Nagaya et al.   DRUG METABOLISM AND DISPOSITION

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

(2020) Carmine Fedele et al.   JOURNAL OF EXPERIMENTAL MEDICINE

KRASG12C inhibitor: combing for combination

(2020) Atanu Chakraborty   BIOCHEMICAL SOCIETY TRANSACTIONS

Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition

(2019) Meagan B. Ryan et al.   CLINICAL CANCER RESEARCH

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

(2019) Brian A. Lanman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the PI3K pathway in cancer: are we making headway?

(2018) Filip Janku et al.   Nature Reviews Clinical Oncology

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer

(2018) Ryan B. Corcoran et al.   Cancer Discovery

COSMIC: the Catalogue Of Somatic Mutations In Cancer

(2018) John G Tate et al.   NUCLEIC ACIDS RESEARCH

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

(2017) Mark Merchant et al.   PLoS One

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

A combinatorial strategy for treating KRAS-mutant lung cancer

(2016) Eusebio Manchado et al.   NATURE

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

(2016) H. Kitai et al.   Cancer Discovery

Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma

(2014) Vito W. Rebecca et al.   Pigment Cell & Melanoma Research

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

(2009) Jens Neumann et al.   PATHOLOGY RESEARCH AND PRACTICE